C ytotoxic antineoplastic therapy is currently one of the most widely used clinical treatments for a range of malignancies. One of the major complications of this therapy, however, is the significant immunodepletion that results, leading to a high degree of morbidity and mortality associated with a depressed immune system (1) (2) (3) . This means that one of the challenges following cytotoxic chemotherapeutic cancer therapy is to enhance the immune system and decrease the associated morbidity and mortality (4) . Furthermore, recovery of CD4 ϩ T cells is critically dependent on a functional thymus (5) , creating further complications in aged patients whose thymi have undergone age-related thymic atrophy.
There is a significant body of research investigating the decline in both thymopoiesis, as well as B lymphopoiesis with age. Studies show that in the bone marrow (BM) 5 there is a loss of early lymphoid progenitors (6 -8) and altered development kinetics of early B cells (6, 8 -14) . This decline in lymphopoiesis leads to reduced B cell emigration from the BM into the periphery (12, 15) , resulting in a reduced Ab repertoire (16 -18) and a reduced production of specific Abs and response to vaccines (19, 20) . In the thymus there is a significant reduction in overall cellularity (21) (22) (23) (24) , a disruption of the thymic architecture, a perturbation of stromal elements (21, 24) and reduced T cell export into the periphery (25) , again leading to a reduced peripheral TCR repertoire and function (26 -32) . Alkylating chemotherapeutic agents, such as cyclophosphamide (Cy), target highly proliferative cells (33, 34) , and as a result, many hematopoietic cells, particularly cells of the lymphoid lineage, are affected (1) . In studies looking at recovery of T cells following immunodepletion in children, it was found that CD4 ϩ cells had numerically and functionally returned to pretreatment levels relatively quickly from intensive chemotherapy (35) , sharing similar reconstitution kinetics to recovery following BM transplant (36, 37) . However, when adults were examined, where thymic atrophy has occurred, CD4 ϩ T cell recovery was significantly impaired and well below pretreatment levels in both models of reconstitution (35, 37) . Furthermore, while CD8 ϩ T cells were restored to pretreatment levels by 6 mo after treatment in both young and old patients (38) , the cells were of predominantly extrathymic origin or due to clonal expansion (39) , suggesting that the recovery of naive T cells in the periphery is critically dependent on thymic function and, as a result, age of the individual (5) . It has been shown that full thymic reconstitution following immunosuppression is possible until middle age, however, in older patients, the peripheral naive TCR repertoire is never completely restored (40) .
As a result of this delay in T cell reconstitution, aged patients treated with the same chemotherapy regime as their younger counterparts are more likely to experience serious posttreatment complications, such as life threatening infections (2, 3) . As a result, aged patients are often given a reduced intensity treatment (41) which, in turn may have adverse effects on long-term cancer-free survival (42) . The effects of chemotherapy, however, are not restricted to T cells with an incomplete recovery of B cells and NK cells in old patients when compared with young adults (40) , leading to a significantly impaired regeneration of the B cell repertoire following chemotherapy in aged mice (43) . These effects on lymphopoiesis are in part due to the effects of Cy on the earliest hematopoietic stem cells (HSCs) which, despite being numerically spared by Cy administration (44, 45) , exhibit a reduced ability to form T cells in vitro in aged and following Cy treatment (46) . Furthermore, Cy treatment disrupts the normal activity of BM stromal cells that support B lymphopoiesis (47) .
Studies have shown that sex steroids are critical mediators of age-related lymphoid declines with age (48 -51) and furthermore, sex steroid ablation (SSA) causes a reversal of thymic (24, (52) (53) (54) and BM (55) atrophy as well as an increase in reconstitution following allogeneic, as well as, autologous HSC transplant (56 -58) . Recent work has also shown that removal of sex steroids enhances both thymic and BM recovery from antineoplastic therapy in young mice (55, 59 ) (unpublished observations).
Although we have previously shown enhanced recovery of BM and thymic lymphopoiesis following cytoablative therapy in young animals, this study sought to answer the more clinically relevant question of the effectiveness of SSA in aged animals, which are more profoundly affected by cytotoxic antineoplastic therapy. These findings provide a solid foundation for the clinical use of SSA, achievable through a reversible chemical process, for immune recovery of aged patients following chemotherapy-improving current treatment outcomes by reducing morbidity and mortality.
Materials and Methods

Animals
Male 2-mo (young controls)-, 9-mo (aged)-, or 24-mo-old C57BL/6J mice were obtained from the Baker Institute Precinct Animal Centre (Melbourne, VIC, Australia), University of Adelaide (Adelaide, SA, Australia), Animal Resource Centre (Perth, WA, Australia) or the Walter and Eliza Hall Institute (Melbourne, VIC, Australia). Mice were maintained at the Precinct Animal Centre (Prahran, Australia) and Mouseworks (Clayton, Australia). Mice were allowed to acclimatize for 7 days before experimentation. All experiments were performed according to animal experiment ethics committee guidelines and approval.
Cy treatment
Mice were injected i.p. with Cy (Endoxan; Baxter Pharmaceuticals) at a dose of 100 mg/kg of body weight per day for 2 days (total dose of 200 mg/kg).
Surgical castration
Mice were anesthetized and a small incision was made in the scrotum. The testes were exposed, ligated with dissolvable sutures, and removed. The wound was closed with dissolvable sutures. For surgical stress control, sham castration was performed as above, but without removal of the testes. Mice were castrated on the day of the second injection.
Flow cytometric analysis
Single cell suspensions of thymus and spleen were obtained by mechanical digestion in cold PBS supplemented with 0.2% BSA. Single cell suspensions of freshly dissected BM were obtained by flushing tibias and femurs with cold PBS supplemented with 0.2% BSA with a 26-gauge needle. The resulting marrow was then suspended by gently pipetting through a 22-gauge needle. Cells were recovered by centrifugation at 470 ϫ g max for 5 min at 4°C. Cell counts were determined by gating viable cells based on cell size using Z2 Coulter Counter (Beckman Coulter).
The following fluorochrome-labeled Abs against murine Ags were used: FITC and PE-conjugated anti-CD3 (clone 145-2C11), FITC, PE and PercPconjugated anti-CD4 (clone RM4-5), PE and PercP-conjugated anti-CD8␣ (clone 53-5.8), allophycocyanin-conjugated anti-TCR␤ (clone H57-597), PEconjugated anti-NK1.1 (clone PK136), PercP-conjugated anti-CD45R/B220 (clone RA3-6B2), FITC or PE-conjugated anti-CD11b (clone M1/70), FITC or PE-conjugated anti-Ly-6G/Ly-6C (Gr-1) (clone RB6-8C5), allophycocyaninconjugated anti-CD117 (c-kit) (clone 2B8), PE-conjugated anti-Sca-1 (clone D7), FITC or PE-conjugated anti-CD11c (clone HL3), FITC or PE-conjugated CD19 (clone 1D3), allophycocyanin-conjugated anti-CD25 (clone PC61), FITC-conjugated anti-CD44 (clone IM7), allophycocyanin-conjugated antiIgM (II/41), PE-conjugated anti-CD43 (S7), PE-conjugated anti-FoxP3.
Triple negative (TN) thymocyte lineage mixture consisted of: CD3, CD4, CD8␣, CD45R (B220), CD11b, and Gr-1. Early T cell progenitor lineage mixture consisted of: CD3, CD8␣, CD19, CD11b, CD11c, Gr-1, NK1.1. CD127, and CD25. Common lymphoid progenitor (CLP) lineage mixture consisted of: CD3, CD4, CD8␣, CD19, CD11b, CD11c, and Gr-1. HSC lineage mixture consisted of: CD3, CD4, CD8␣, B220, CD11b, CD11c, and Gr-1. Streptavidin-FITC, PE, PercP, and allophycocyanin also were obtained from BD Pharmingen.
All conjugates were purchased from either BD Biosciences or eBiosciences except anti-CD127 PE, which was purchased from Chemicon International. All cells were analyzed on a multiparameter FACSCalibur (BD Biosciences) using CellQuest Pro (BD Biosciences) or FlowJo (Treestar) software.
T cell proliferation assay
Splenocytes (5 ϫ 10 5 cells/well) were stimulated with plate bound ␣CD3 (clone 145-2c11) at 10, 5, 2.5, and 1.25 g/ml and ␣CD28 (clone 37.51) at 5 g/ml. Cells were cultured for 4 days and pulsed with 1 Ci/well 
Hepatitis B vaccination schedule and serum collection
At 2 or 6 wk following surgery, mice were vaccinated with s.c. injections of 500 l of H-B-VaxR II (CSL Limited) at a concentration of 5 g/ml in the presence of aluminum hydroxide. This was repeated 3 times 2 wk apart to give a total of three vaccinations per mouse. Fourteen days following the final vaccination mice were sacrificed and serum was collected for analysis of Ab titer. At 2 and 6 wk following surgery (sham-SSA/SSA or sham-SSA ϩ cyclo/SSA ϩ cyclo) 500 l of blood was collected by cardiac puncture. Blood was allowed to clot for 4 h at room temperature. Samples were then centrifuged at 855 ϫ g max for 3 min. Serum was collected and frozen at Ϫ20°C until ELISA was performed.
ELISA
Abs against hepatitis B vax were detected using ELISA. Maxisorb Immunplates (Nunc) were coated with 100 l of hepatitis B small surface Ag (HbsAg; provided courtesy of Hans Netter, Monash University, Australia) at a concentration of 500 ng/ml overnight at 4°C. Before ELISA was performed, the plate was blocked with 10% skim milk powder in PBS for 2 h to block any nonspecific binding of Ag. Plates were incubated with 100 l of 2-fold serum dilutions for 1 h at 37°C. Specific Abs were detected by reaction with HRPlabeled goat anti-mouse IgG (Sigma-Aldrich) followed by enzyme substrate (H 2 O 2 /OPD) and visualized by measuring the absorbance at 492 nm using a Bio-Rad Benchmark Plus microplate spectrophotometer.
Statistical analysis
Statistical analysis to compare means of cell numbers as well as counts in proliferation assays were performed with the nonparametric, unpaired MannWhitney U test using SPSS or Graphpad Prism software. Statistical differences between Ab titers measured by ELISA were calculated using Student's t test. A value of p Յ 0.05 was considered to be statistically significant.
Results
Previous work in our laboratory has shown that thymic recovery following antineoplastic therapy is enhanced following withdrawal of sex steroids (G. L. Goldberg, J. A. Dudakov, N. Seach, J. J. Reiseger, T. Uen., K. Vlahos, M. V. Hammett, L. F. Young, T. S. P. Heng, R. L. Boyd, and A. P. Chidgey, manuscript in preparation). To examine whether the same holds true in aged mice, which have a significant thymic defect before Cy treatment, aged mice were surgically castrated (SSA) or sham-castrated (sham-SSA) and injected with a clinically relevant dose of CY (100 mg/kg/day) on days Ϫ1 and 0 before surgery.
SSA enhances thymic recovery following anti-neoplastic therapy in aged mice
Following Cy treatment, thymic cellularity is significantly decreased in sham-SSA mice, a result that is not rectified until 28 days after treatment (Fig. 1A ). Mice that have been SSA had significantly increased thymus cellularity compared with sham-SSA control mice over all time points examined. Furthermore, SSA restored thymic cellularity to untreated aged levels by day 7. Thymi of SSA, Cy-treated mice were hypertrophic compared with both untreated young and aged mice by day 14, a level that was FIGURE 1. Sex steroid ablation of Cy-treated aged mice restores thymic cellularity and TN, DP, and SP thymocyte numbers. A, Total thymus cellularity from untreated 2-and 9-mo (n ϭ 11 and 6, respectively), Cy-treated 9-mo sham-SSA (n ϭ 10 at each time point) or SSA (n ϭ 10 at each timepoint) mice 
compared with sham-SSA 9-mo Cy-treated ‫)ء(‬ mice, untreated 2-mo mice (∧) and untreated 9-mo agematched mice ( †). 
FIGURE 2. Reconstitution of intrathymic T cell progenitors following Cy treatment is enhanced by SSA. Absolute numbers of Lin
Ϫ CD44 ϩ CD25 Ϫ TN-1 thymocytes, Lin Ϫ IL7R␣ ϩ B220 ϩ ckit Ϫ CLP-2 cells, IL7R␣ Ϫ TN-1 thymocytes, Lin Ϫ IL7R␣ Ϫ CD44 ϩ CD25 Ϫ ckit ϩ ETPs, transitional Lin Ϫ CD44 ϩ CD25 low TN1-2 thymocytes, Lin Ϫ CD44 ϩ CD25 ϩ TN2 thymocytes, Lin Ϫ CD44 Ϫ CD25 ϩ TN3
CD8
Ϫ cells showed the most resistance to Cy treatment, with little decline in number, but also no change as a result of SSA (Fig. 1B) , a result that may be explained by the heterogeneity of this subset. CD4 ϩ
ϩ double positive (DP), CD4 ϩ and CD8 ϩ single positive (SP) cells all showed similar kinetics following Cy treatment and sex steroid withdrawal. After a decrease in number due to Cy treatment, in sham-SSA mice, cellularity was restored to untreated aged levels by day 14 (DP) or 28 (SP). Following SSA, there was a significant increase in the number of all these subsets compared with sham-SSA controls by 14 days after treatment, with greater than untreated levels observed from day 14 (DP and CD4 ϩ SP) and day 28 (CD8 ϩ SP).
Enhanced thymic recovery from anti-neoplastic therapy due to SSA is mediated by increased intrathymic progenitors
To examine the mediators of enhanced recovery following SSA, early intrathymic T cell progenitors were examined. Triple Results are expressed as mean Ϯ SEM for each group at each time point. Data are cumulative of two or more independent experiments. ‫∧/ †/ء‬ (p Յ 0.05); ‫∧∧/ † †/ءء‬ (p Յ 0.01); ‫∧∧∧/ † † †/ءءء‬ (p Յ 0.001) compared with sham-SSA 9-mo Cy-treated ‫)ء(‬ mice, untreated 2-mo mice (∧) and untreated 9-mo age-matched mice ( †).
negative (TN)1 cells were depleted as a result of Cy treatment but were restored to untreated levels by day 14 (Fig. 2) . Following SSA, there was a significant increase in these TN1 cells, compared with both sham-SSA and untreated young and aged controls, from day 14 after surgery, an increase that is maintained until at least day 42. There was little Cy-induced depletion within the non-canonical Lin Ϫ IL7R ϩ B220 ϩ ckit Ϫ population of TN1, a subset that contains the CLP-2 precursor. However, from 7 days following SSA, there were significant increases when compared with sham-SSA mice and, in fact, were greater than untreated mice at all time points. Residing within the IL7R␣ Ϫ fraction of TN1 cells are the canonical ckit ϩ ETPs (falling in the TN1a/b/c fraction) and noncanonical ckit Ϫ TN1d and e cells (60) . Total IL7R␣ Ϫ TN1 and ETP cells showed significant Cy-induced depletion in sham-SSA mice that was not restored to untreated levels until 28 days after surgery. Although there was no effect of SSA on either population at the early time point, by day 14 there was a significant increase in the number of these cells compared with both sham-SSA and untreated controls.
Similar levels of depletion were observed in the transitional TN1-2 as well as the T cell committed TN2-4 populations as a result of Cy treatment. There was a significant increase in the number of all these subsets (except TN4) from day 7 compared with sham-SSA and day 14 compared with untreated groups. Within the most developmentally mature TN4 (pre-DP) population, there was no change at day 7, with a significant effect of SSA being observed from day 14 and maintained until at least day 42.
SSA enhances recovery of BM lymphopoiesis following anti-neoplastic therapy in aged mice
Total BM cellularity was not severely depleted as a result of Cy treatment (Fig. 3A) . By day 14 after SSA, there were significantly more cells in the BM of SSA, compared with sham-SSA and untreated mice. To assess what contributed to this increased cellularity, HSCs, lymphoid precursors, and developing B cells were examined.
The Lin Ϫ ScaI ϩ ckit ϩ (LSK) fraction of BM that contains all HSCs as well as their downstream progeny can be subdivided based on Flt3, expression of which is associated with a loss of self-renewal capacity (61) . Long-term HSCs can be distinguished from multipotent progenitors (MPPs) phenotypically by differential Flt3 expression and by their functional potential to mediate stable long-term hematopoietic engraftment (62) (63) (64) . Furthermore, high levels of Flt3 can be used as a marker enriching for lymphoidprimed multipotent progenitors (65, 66) .
Following treatment with Cy there was a significant depletion of both Flt3
Ϫ (containing long-and short-term repopulating HSCs) and Flt3 ϩ (containing MPPs and lymphoid-primed multipotent progenitors). Both these populations had been restored to untreated levels by day 14 and were increased above control untreated levels in the Flt3 ϩ LSK cells in sham-SSA mice from day 28 (Fig. 3B ). In both populations there was a significant increase as a result of SSA compared with sham-SSA mice from day 14 through day 42. To examine the impact of Cy treatment and SSA on early lymphoid cells, we examined IL7R␣ ϩ committed lymphoid precursors, including the classic CLP-1 and the more recently described CLP-2 (67) and early progenitor with lymphoid and myeloid capacity (EPLM) (68) (Fig. 3C) . Interestingly the EPLM population was the only committed progenitor to be depleted at day 7 with both CLP-1 and CLP-2 cells actually increased in sham-SSA mice at the same time point. In both the CLP populations, levels remain elevated in sham-SSA mice for up to 42 days after surgery. BM CLP-2 cell number was significantly increased, both a result of SSA and, interestingly at day 14 a direct result of Cy treatment (Fig. 3, C and D) . This elevation caused by Cy was so severe that in sham-SSA animals there was an 11-and 30-fold increase at day 14 compared with untreated 2-mo or 9-mo mice, respectively. Despite these profound increases as a result of Cy treatment, SSA further increased the number of CLP-2 cells so that at the same time point there was a 50-fold and 130-fold increase compared with untreated young and aged mice, respectively. Although not as dramatic an increase as the CLP-2 population following SSA, there were significant increases in the number of CLP-1 and EPLM cells up to 42 days after surgery.
To assess the impact that these changes in lymphoid progenitors had on BM lymphopoiesis, developing B cells were examined. Cy treatment significantly depleted the proportion (Fig. 3E ) and number (Fig. 3F ) of total B220 ϩ B cells in both sham-SSA and SSA animals. SSA significantly enhanced total B cell recovery, surpassing untreated young and aged control mice. There was a significant decrease in the number of all developing B cells as a result of Cy treatment in sham-SSA mice. This decline took at least 14 days (pro-and pre-B cells) and up to 42 days (imm-B cells) to be restored to untreated levels (Fig. 3F) . Following SSA, there was a rapid restoration of B cell numbers compared with sham-SSA controls in all subsets from day 7, even reaching above control levels by day 14.
Withdrawal of sex steroids enhances peripheral T cell number and function without perturbing regular V␤ usage
To examine whether enhanced thymocyte recovery translated into the periphery, splenic T cells were examined following Cy treatment with or without SSA. Although there was little change in total splenic cellularity as a result of Cy treatment, following SSA there was a significant increase from day 14 to 42 following treatment (Fig. 4A) . There was a significant decrease in the number of both CD4 ϩ and CD8 ϩ T cells in the spleen following Cy treatment until day 42 and day 28, respectively (Fig. 4, B and C) . Following SSA, there was a significant increase in both CD4 ϩ and CD8 ϩ T cells from day 14 after treatment. This was maintained until at least day 42, peaking at day 28. Naive (CD62L ϩ CD44 Ϫ ) and memory (CD62L Ϫ CD44 ϩ ) CD4 ϩ and CD8 ϩ T cells were both significantly decreased as a result of Cy treatment (Fig. 4, B and C) . Following SSA there was a significant increase in the number of both naive and memory cells, compared with sham-SSA controls, from as early as day 14 after treatment. Interestingly, the ratio of naive to memory cells, which declines as a result of Cy treatment, is restored more quickly in castrate mice. However, this enhanced ratio in SSA mice is normalized by day 28 (CD4 ϩ ) and 42 (CD8 ϩ ). To assess the function of T cells in the periphery, proliferation was measured following stimulation with anti-CD3 and anti-CD28. Counts were normalized per 10 4 T cells cultured to accommodate for changes in cell number following SSA (Fig.  5A) . At both day 14 and day 42, there was a significant decrease in the proliferation of T cells following Cy treatment. Although there was limited improvement in T cell proliferation following SSA at day 14, there was a significant increase in their proliferation by day 42.
V␤ usage was analyzed following Cy treatment and SSA (Fig.  5B) . In both CD4
ϩ and CD8 ϩ cells there was no difference in V␤ usage when comparing sham-SSA and SSA mice.
Regulatory T cells (Tregs) are defined as being CD4 ϩ CD25 ϩ FoxP3 ϩ . These cells were analyzed following Cy treatment and SSA; FoxP3 ϩ Tregs were decreased significantly in number at day 7 after Cy treatment in both sham-SSA and SSA groups (Fig. 5C ), which was normalized by day 14. From day 28 to day 42, there was a significant increase in the number of these cells following SSA, reaching higher levels than both untreated young and aged controls.
Withdrawal of sex steroids increases peripheral B cell export and humoral immune function following anti-neoplastic therapy
To examine whether enhanced B cell recovery following Cy treatment was reflected in the periphery, spleens of sham-SSA, and SSA mice were examined. There was a significant decrease in the number of peripheral B cells following Cy treatment which does not fully recover, even 42 days after treatment (Fig. 6A) . Following SSA there was little change until day 14 when there was a significant increase in the number of cells, which was maintained until day 42. This correlates to the time it takes for B cells to develop in the BM and is likely to be a result of increased BM export of recently developed B cells. SSA mice had fully recovered to untreated levels by day 28 and, in fact, were above control levels at this time point. To determine whether these increases in B cell number resulted in an increase in B cell function, BALB/c mice were challenged with a hepatitis B vaccine and the Ab titer against viral peptide was measured by ELISA (Fig. 6B) . At 14 days after Cy treatment, when the first cohort of B cells developed since surgery would have been exported into the periphery, there was still a significant decrease in the Ab titer, compared with untreated controls, in both sham-SSA and SSA mice. However, despite not having reached untreated levels, there is still a significant increase in the Ab titer following SSA. Six weeks after treatment, Ab titers in both sham-SSA and SSA mice had still not returned to untreated levels. However, there was a much greater difference between sham-SSA and SSA mice with a significant increase in the titer of Ab against peptide after SSA.
SSA enhances hematopoietic recovery in very old mice
To assess whether observations in 9-mo mice, analogous to middle age in humans, could be translated into very old patients, 24-mo mice were treated with 200 mg/kg Cy and then surgically sham-SSA or SSA. Bone marrow and thymus were examined 21 days after treatment. Interestingly, within the thymus, Cy treatment was insufficient to further deplete thymic cellularity (Fig. 7A) . However, following SSA there was a significant increase in all thymocyte subsets examined; ETP and TN1-4 (Fig. 7B) ; DN, DP, CD4 ϩ , and CD8 ϩ (Fig. 7C) . In the BM, there was little depletion as a result of Cy treatment with a significant increase as a result of SSA observed (Fig. 7D) . There was little change among any of the progenitor cells examined except the CLP-2 subset, which was significantly increased as a result of SSA (Fig. 7E) . Within the developing B cells, however, there was significant depletion of pre-B and imm-B cells, leading to an overall decrease in total B cells, as a result of Cy treatment (Fig. 7F) . Following SSA, there was little effect on the earliest pro-B cells; however, within the pre-B and imm-B cell subsets, there was a significant increase in the number of these cells.
Discussion
This study shows that recovery of lymphopoiesis from antineoplastic therapy in aged mice, in both thymus and BM, can be significantly enhanced following SSA. This astounding improvement in immune recovery is potentially clinically groundbreaking in its novel ability to reduce the incidence of posttreatment infections and mortality.
Reduction in lymphocytes, and in particular T cells, is a detrimental side effect to chemotherapy treatment (1, 4, 34, 39) . Restoring thymic cellularity following immunodepletion is an important step in improving treatment outcomes, particularly in aged patients, which already have a depressed immune system to begin with (5, 36, 37, 40, 69, 70) . We and others have previously shown that SSA regenerates the age-associated atrophic thymus and increases peripheral export of naive T cells (24, 53, 54, 59) . Furthermore, in young animals treated with Cy, SSA significantly enhances lymphopoiesis in both the thymus and BM (59) (unpublished observations). Here we show that in 9-mo and 24-mo aged mice, which have substantially involuted thymi, SSA restores thymic cellularity following Cy treatment to surpass levels in both untreated young and aged mice. This increase in total cellularity is reflected by increases within individual thymocyte populations and the earliest intrathymic T cell precursors, including both canonical and noncanonical progenitors. Interestingly, even in sham-SSA mice, intrathymic ckit Ϫ IL7R␣ ϩ B220 ϩ , or non-canonical T cell precursors, were distinctly unaffected by Cy treatment. This same population, even in sham-SSA controls, was significantly enriched in the BM of aged mice and similarly enriched in the thymus of young mice following treatment with Cy (55) (unpublished observations). Taken together with studies identifying non-canonical T cell progenitors within the heterogeneous TN1 population (60) as well as cells that have undergone extrathymic Notch-driven Tlineage commitment (71) , supports the finding that a population of extrathymic committed T cell progenitors may well aid in the early regeneration of thymopoiesis in a damage model (72) .
Depletion of immune system function following chemotherapy is not restricted to T cells, with significantly impaired regeneration of B cell number (1) as well humoral function observed (43) . Cy has also been shown to directly affect HSCs in the BM and their ability to generate downstream lymphoid progeny (45, 46) . Taken together, these results indicate that any treatment designed to enhance immunity following chemotherapy will not only have to restore thymic function, but also impact on the ability of the BM to support hematopoiesis. As expected, there was only minimal depletion of HSCs after Cy treatment (44, 73) , the loss being restricted to the more highly proliferative Flt3 ϩ MPPs. Of note was the rapid increase in the number of both Flt3
Ϫ and Flt3 ϩ LSK cells beyond levels that are observed in untreated young and aged mice. Interestingly, we observed no depletion within the IL7R␣ ϩ ckit ϩ FIGURE 7. Enhanced hematopoietic recovery from Cy treatment occurs in very old mice. A, Total thymic cellularity from untreated 24-mo (n ϭ 4) and Cy-treated sham-SSA (n ϭ 7) or SSA (n ϭ 6) 24-mo mice 21 days after surgery. CLP-1 population, although it is possible that by 7 days after treatment their numbers have already been restored. Following SSA, there is a significant increase in all committed lymphoid progenitors analyzed that, taken together with increased LSK cells, forms the basis for increases in downstream developing B and T cells. Cy treatment also significantly depleted all B cell subsets examined with the most profoundly affected cells being the more highly proliferative pre-B and imm-B cells (55) . Reflecting the results found in the thymus, by day 14 SSA significantly restored B cells to levels even greater than those in young untreated control mice. The increase in B cells was evident in all subsets even by day 7, suggesting a general boost to all B cells rather than triggering an increased supply of progenitors to initiate these increases. The impact of SSA is not restricted to the primary immune organs, however, with a significant conversion of developing lymphocytes into the periphery following SSA. This resulted in an increase in both naive and memory CD4 ϩ and CD8 ϩ T cells from day 7, suggesting both enhanced thymic export as well as peripheral expansion. Considering that peripheral T cells have been shown to express a functional androgen receptor (74) it is also possible that removal of a negative stimuli such as sex steroids, which can directly increase apoptosis and decrease proliferation in T cells (75, 76) , can contribute to the increased levels of peripheral T cells including memory T cells. Functionally, T cells in the periphery were found to be more responsive to proliferative stimulation following SSA on a per cell basis and their V␤ usage was unperturbed, suggesting that normal T cell development has been restored, and in fact are functionally improved. Within the FoxP3 ϩ Tregs we found that despite being significantly depleted by Cy treatment, there was a delayed recovery in these cells compared with ␣␤-TCR ϩ cells, with no significant difference between SSA and sham-SSA control mice until day 28 when there was a hypertropic increase in SSA-treated mice. This either represents delayed kinetics of thymic generation, or a consequence of the need for IL-2 producing mature CD4 ϩ T cells to be re-established (77) . This increase in immunosuppressive Tregs is unlikely to adversely affect patients in the clinical setting; it more likely represents a re-establishment of normal T cell homeostasis.
Similar to results observed in young Cy-treated mice (55), SSA significantly enhanced conversion of developing B cells from the BM into the periphery to pretreatment levels by day 14 whereas sham-SSA mice had not recovered until 42 days. Furthermore, sustained increases above sham-SSA animals imply the lasting impacts of SSA. Ab titer in response to the hepatitis B virus vaccine was also significantly increased in SSA animals at days 14 and 42 following surgery suggesting that the function of these peripheral B cells has also been enhanced. However, the limitation of this assay is that it does not take into account the increased number of B cells in the periphery following SSA.
In old patients, it is sometimes not feasible to be giving treatments for malignancies due to the immunosuppression associated with chemotherapy treatment of aged patients (1, 2, 70) . It was found that in very old 24-mo mice, in marked contrast to 9-mo Cy-treated mice, there was minimal deleterious impact of Cy treatment on either thymocyte or BM cellularity. In both cases this may mean that older cells are more quiescent and hence less susceptible to Cy and/or may reflect the already severely involuted thymus, which is roughly one quarter the total cellularity as at 9-mo and hence may have already reached its nadir. It is interesting to note that the more mature CD4 ϩ and CD8
ϩ SP thymocytes were significantly depleted compared with untreated control mice. However, SSA significantly improved thymic cellularity over and above untreated and sham-SSA control levels. Similarly in the BM, B lymphopoiesis was significantly improved despite little Cy-induced depletion of lymphoid precursors and HSCs. These results suggest that the effects of SSA on increasing the number of lymphocytes are not dependent on the prior degeneration of these subsets as a result of age or chemotherapy treatment.
While the precise mechanisms of SSA-mediated increase in immune system recovery have not yet been fully elucidated, our previous studies have indicated that a major target is the supporting microenvironments that switch between production of immunosuppressive cytokines (such as TGF␤) toward pro-lymphopoietic cytokines (such as IL-7 and keratinocyte growth factor) (48, 56, 57, 78) . Furthermore, increased levels of the chemokine CCL25 can influence the uptake of progenitors from the circulation following SSA (79) .
In this study, it was found that withdrawal of sex steroids profoundly enhanced thymic, BM, and peripheral recovery from cytotoxic anti-neoplastic therapy in aged and old mice. Our previous findings have shown that SSA is effective in enhancing recovery from cytoablative therapies in young animals, these results provide a proof-of-principle concept that SSA can be used in old patients to aid in immune recovery, therefore enhancing treatment outcomes.
